reports
- Martin Hall
Hardman & Co Healthcare Index: 2025 – Index rose, but another tough ye...
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. After three years of annual declines, the HHI rebounded 17.6% to 469.1 in 2025. While this sounds positive, it was below the strong performance of most major UK healthcare stocks and, in general, it underperformed its UK and peer benchmarks: FTSE 100 (+21.5%); FTSE All-Share (+19.8%); and the NASDAQ Biotech Index (NBI; +32.4%). Th...
- Carole Braudeau
Credit Morning 12/22/2025
Paris prosecutor's office launches probe into Uranium theft from Somaïr in Niger|Maxeda: weak Q3 results and announcement of restructuring process|Coty appoints Markus Strobel as new chairman and interim CEO|Golden Goose: HSG acquires majority stake|The Belgian government is considering increasing its stake in Ageas according to the Belgian newspaper de Tijd|
- Carole Braudeau
Morning Crédit 22/12/2025
Enquête du parquet de Paris sur le vol d’Uranium de la Somaïr au Niger|Maxeda : faibles résultats T3 et annonce du processus de restructuration|Coty nomme Markus Stroble comme nouveau Chairman et CEO par interim|Golden Goose : HSG acquiert une part majoritaire au capital|Le gouvernement belge envisageait d'augmenter sa participation dans Ageas selon le journal belge De Tijd|
- Carole Braudeau
- Carole Braudeau
- Dominic Rose
- Naresh Chouhan
Thematic - 2026 Outlook - "5 More Years" (55pgs)
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
GSK: 1 director
A director at GSK sold 6,000 shares at 1,829p and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close p...
- Carole Braudeau
Credit Morning 11/13/2025
Carrefour: Saadé family acquires stake, Peninsula exits|Emeria: an equity fundraising to enable bond refinancing?|Advanz Q3 25 results: Adj. EBITDA drops yoy and net leverage increases further – but not surprising|grenke Q3 25 results: Good operational performance YTD, but loss rate and NPLs increase|Finnair: no surprises on the FY 2026-2029 targets at first sight|
- Carole Braudeau
Morning Crédit 13/11/2025
Carrefour : entrée de la famille Saadé au capital et sortie de Peninsula|Emeria : une levée d’equity pour permettre le refinancement des obligations ?|Advanz Q3 25 results: Adj. EBITDA drops yoy and net leverage increases further – but not surprising|grenke Q3 25 results: Good operational performance YTD, but loss rate and NPLs increase|Finnair: no surprises on the FY 2026-2029 targets at first sight|
- Carole Braudeau
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
ETL EUTELSAT COMMUNICATIONS SA
NK IMERYS SA
RNO RENAULT SA
DAI DAIMLER AG
EN BOUYGUES SA
GRF GRIFOLS S.A. CLASS A
FRE FRESENIUS SE & CO. KGAA
VOW3 VOLKSWAGEN AG PREF
RACE FERRARI NV
GEST GESTAMP AUTOMOCION S.A.
NEXI NEXI S.P.A.
STLA STELLANTIS N.V.
- Konrad Zomer
PUB PUBLICIS GROUPE SA
BVI BUREAU VERITAS SA
KPN ROYAL KPN NV
EN BOUYGUES SA
DEMANT DEMANT A/S
WKL WOLTERS KLUWER NV
ITRK INTERTEK GROUP PLC
VNA VONOVIA SE
GRF GRIFOLS S.A. CLASS A
FRE FRESENIUS SE & CO. KGAA
NEM NEMETSCHEK SE
EVK EVONIK INDUSTRIES AG
RACE FERRARI NV
GRF.P GRIFOLS S.A. PREF CLASS B
AD KONINKLIJKE AHOLD DELHAIZE N.V.
BP. BP P.L.C.
BIM BIOMERIEUX SA
SHL SIEMENS HEALTHINEERS AG
CCEP COCA-COLA EUROPEAN PARTNERS PLC
NEXI NEXI S.P.A.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
SGSN SGS SA
NOVO B NOVO NORDISK A/S
QGEN QIAGEN N.V.
- Carole Braudeau
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
ETL EUTELSAT COMMUNICATIONS SA
NK IMERYS SA
RNO RENAULT SA
DAI DAIMLER AG
EN BOUYGUES SA
GRF GRIFOLS S.A. CLASS A
FRE FRESENIUS SE & CO. KGAA
VOW3 VOLKSWAGEN AG PREF
RACE FERRARI NV
GEST GESTAMP AUTOMOCION S.A.
NEXI NEXI S.P.A.
STLA STELLANTIS N.V.
- Konrad Zomer
PUB PUBLICIS GROUPE SA
BVI BUREAU VERITAS SA
EN BOUYGUES SA
DEMANT DEMANT A/S
WKL WOLTERS KLUWER NV
ITRK INTERTEK GROUP PLC
VNA VONOVIA SE
GRF GRIFOLS S.A. CLASS A
FRE FRESENIUS SE & CO. KGAA
NEM NEMETSCHEK SE
EVK EVONIK INDUSTRIES AG
RACE FERRARI NV
GRF.P GRIFOLS S.A. PREF CLASS B
AD KONINKLIJKE AHOLD DELHAIZE N.V.
BP. BP P.L.C.
BIM BIOMERIEUX SA
SHL SIEMENS HEALTHINEERS AG
CCEP COCA-COLA EUROPEAN PARTNERS PLC
NEXI NEXI S.P.A.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
SGSN SGS SA
NOVO B NOVO NORDISK A/S
QGEN QIAGEN N.V.
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Juan Ros-Padilla
- Carole Braudeau
- Chaima Ferrandon
- Sven Edelfelt
HEIA HEINEKEN NV
EDEN EDENRED SA
IPN IPSEN SA
ENGI ENGIE SA.
BNP BNP PARIBAS SA CLASS A
ADS ADIDAS AG
FGR EIFFAGE SA
ULVR UNILEVER PLC
GLE SOCIETE GENERALE S.A. CLASS A
KBC KBC GROUP N.V.
OR L'OREAL SA
RAND RANDSTAD NV
GRF GRIFOLS S.A. CLASS A
ANA ACCIONA SA
GRF.P GRIFOLS S.A. PREF CLASS B
AKZA AKZO NOBEL N.V.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
- Carole Braudeau
- Chaima Ferrandon
- Sven Edelfelt
HEIA HEINEKEN NV
EDEN EDENRED SA
IPN IPSEN SA
ENGI ENGIE SA.
BNP BNP PARIBAS SA CLASS A
ADS ADIDAS AG
FGR EIFFAGE SA
ULVR UNILEVER PLC
GLE SOCIETE GENERALE S.A. CLASS A
KBC KBC GROUP N.V.
OR L'OREAL SA
RAND RANDSTAD NV
GRF GRIFOLS S.A. CLASS A
ANA ACCIONA SA
GRF.P GRIFOLS S.A. PREF CLASS B
AKZA AKZO NOBEL N.V.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.